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A low-pathogenicity avian influenza H6N2 virus was used to investigate approaches to 
improve DNA vaccine efficacy. The viral hemagglutinin (HA) gene or its chicken biased 
HA gene, incorporating a Kozak sequence, was cloned into a pCAGGS vector to produce 
the pCAG-HAk and pCAG-optiHAk constructs. Following two intramuscular injections, 
the seroconversion rate in vaccinated chickens with 10, 100 or 300 µg pCAG-HAk were 
87.5%, 75% and 75% respectively. The profile of H6 hemagglutination inhibition (HI) 
antibodies induced by different doses of pCAG-HAk during the 8-week study period was 
similar. The HI titer rose significantly in the three different dose groups following the 
booster and reached a plateau 2-3 weeks post-booster. In a single dose vaccination group 
with 100 µg pCAG-HAk, a maximum seroconversion rate reached 53.3% at 5 weeks 
post-vaccination. The earliest time of seroconversion appeared two weeks after DNA 
immunization. Following two electroporation (EP) vaccinations with 100 µg pCAG-HAk, 
all birds seroconverted and the HI antibody titers were significantly higher than those 
using intramuscular immunization, suggesting that EP was more efficient than 
intramuscular delivery of the DNA vaccines.  In comparison, chickens immunized with 
10 or 100 µg pCAG-optiHAk showed 37.5% and 87.5% seroconversion rates 
respectively at 3 weeks following the booster. The pCAG-HAk was not significantly 
different from the pCAG-optiHAk in either the seroconversion rate or H6 HI titer, 











suggesting that the codon-optimized HA DNA vaccine did not achieve significantly 
better immunogenicity than the pCAG-HAk vaccine. 
 
Keywords: Avian influenza; H6 subtype; DNA vaccine; Codon optimization; 
Electroporation; Chickens 
1. Introduction  
 
DNA vaccines have been developed to protect against a number of pathogens in a range 
of animals following the first report that direct injection of plasmid DNA generated the 
successful expression of the plasmid-encoded antigen in murine muscle cells (Wolff et al., 
1990). However, low and variable antibody response has been a critical problem 
hindering  commercial DNA vaccine development (Abdulhaqq and Weiner 2008). In 
response, a diverse range of strategies have been developed to address the factors that 
limit immune responses to DNA vaccines. However, little data are available to indicate 
which of these strategies will be most useful and practical.  
Successful DNA vaccination requires high expression of genes derived from 
microorganisms in animals and humans.  The Kozak sequence plays a major role in the 
initiation of a translation process in mammalian cells by slowing down the rate of 
scanning by the ribosome and increasing the chance of the ribosome recognizing the start 
of translation at the AUG start codon (Kozak 1987). Insertion of a Kozak sequence into a 
gene of interest or into an expression vector has been used to develop DNA vaccines 
against Chikungunya virus (Muthumani et al., 2008) and HIV (Kumar et al., 2006), and 
for minigene DNA vaccines (An et al., 2000).  
It is known that mammalian codon usage patterns are different from those of numerous 
microorganisms and yeasts (Ikemura 1985). Thus, differences in codon usage between a 
heterologous gene and the host organism may have an impact on expression of the gene, 











which may eventually affect the immunogenicity of an antigen-encoding DNA vaccine. It 
was reported that codon optimization was effective in enhancing the immunogenicity of 
DNA vaccines against influenza virus (Wang et al., 2006), H5 AIV (Jiang et al., 2007), 
HIV (Andre et al., 1998)   and Mycobacterium tuberculosis (Ko et al., 2005).  
Intramuscular (IM) vaccination has been used widely, however, it does not appear 
particularly efficient at inducing immune responses by DNA vaccination, as plasmid 
DNA administered by IM route was poorly distributed, inefficiently expressed, and 
rapidly degraded (Wang et al., 2008). Physical methods, such as a gene gun and 
electroporation (EP), have been shown to elicit better immune responses in large animals 
and humans (Wang et al., 2008). Although the gene gun technology was regarded as an 
effective method for DNA vaccination, this method is currently impractical for poultry 
due to the inability to vaccinate large numbers of birds and the high cost of the carrier 
beads (Kodihalli et al., 1997). In vivo electroporation has been demonstrated to improve 
the efficacy of DNA vaccination in eliciting both humoral and cellular immune responses 
in mice, rats, guinea pigs and rabbits (Widera et al., 2000; Zucchelli et al., 2000).  
DNA vaccines encoding HA genes of influenza type A viruses have been reported to 
generate variable immune responses in several different species, including mice 
(Montgomery et al., 1993) , chickens (Kodihalli et al., 1997), swine (Macklin et al., 1998), 
ferrets (Ljungberg et al., 2002) and nonhuman primates (Liu et al., 1997). In our previous 
experiments, IM injection of four DNA constructs encoding the same HA gene of an 
avian influenza H6N2 virus in different expression vectors (VR1012, pCI, pCI-neo and 
pVAX1) induced no or marginal antibody response in chickens (Shan 2010). In this study 
strategies were investigated to improve the immune responses to a DNA vaccine 











encoding the HA gene of a H6N2 low pathogenicity avian influenza (LPAI) virus in a 
pCAGGS vector in chickens. The strategies investigated with this vector included 
insertion of a Kozak sequence, use of a chicken codon optimized HA gene and use of EP, 
in an attempt to improve the efficacy of DNA vaccines.     
2. Materials and methods 
 
2.1. Animals, viruses and cells 
 
The LPAI virus used for these studies, A/Eurasian coot/Western Australia/2727/79 
(A/coot/WA/2727/79) (H6N2), was propagated and titrated as 50% egg infectious 
doses/0.1 mL (EID50/0.1 mL) as described previously (Shan et al., 2010). 
Three-week-old SPF chickens were housed, fed and watered in high efficiency particulate 
air (HEPA)-filtered poultry isolators according to the experimental protocol approved by 
the Animal Ethics Committee of the Harbin Veterinary Research Institute, Chinese 
Academy of Agricultural Sciences, Harbin, China.  
In vitro expression of the DNA vaccine construct was conducted in a human embryonic 
kidney cell line, 293T cells, and also in primary cultures of chicken embryo fibroblast 
(CEF) cells prepared as described previously (Shan, 2010).  The cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with10% foetal calf serum, 
100 U/ml penicillin and 100 µg/ml streptomycin at pH 7.2  and 37 °C in a 5% carbon 
dioxide atmosphere.  
2.2. Construction of expression plasmid (pCAG-HAk and pCAG-optiHAk) 
 
Amplification of the full-length open reading frame (ORF) of the HA of 
A/coot/WA/2727/79 (H6N2) was performed using the primers 











5’ATGATTGCAATCATAATATTC3’ and 5’TTATATACATATCCTGCATTG3’.  A 
Kozak sequence (GCCGCCACC) was inserted before the ATG start codon, an EcoRI site 
was added upstream of the Kozak sequence and a SmaI site was added to the 5’end of the 
downstream primer. The primers were synthesized by GeneWorks (GeneWorks Pty. Ltd., 
Australia). The HA gene extracted from virus infected allantoic fluid was amplified by 
proof-reading PCR using the PhusionTM high-fidelity DNA polymerase protocol 
(Finnzymes OY, Finland) according to the manufacturer’s instructions, and was 
subsequently cloned into the plasmid vector pCAGGS (kindly provided by Dr. Y. 
Kawaoka) to generate the DNA construct pCAG-HAk. The pCAGGS plasmid is a 
monocistronic vector which contains the chicken β-actin promoter and the human CMV-
IE enhancer, the SV40 origin of replication and the rabbit β-globulin polyadenylation 
signal. 
The sequence of the full-length HA gene from A/coot/WA/2727/79 (H6N2) was shifted 
to the chicken-biased codons using DNASTAR from a codon usage database 
(http://www.kazusa.or.jp/codon/). The Kozak sequence and restriction endonuclease site 
sequences for EcoRI and SmaI were included at the appropriate locations as described 
above, and this codon-optimized HA gene was chemically synthesized by GenScript 
Corporation (Beijing, China). The synthesized codon-optimized HA gene insert was 
subcloned into the pCAGGS vector to generate the DNA construct pCAG-optiHAk. 
Plasmids pCAG-HAk, pCAG-optiHAk and pCAGGS were amplified in E.coli DH5α 
(TaKaRa, China) and extracted using the alkaline lysis method (Sambrook and Russell 
2001). After purification by polyethylene glycol (PEG8000) precipitation, the plasmids 











were quantified by ultraviolet spectrophotometer (Ultrospec3000, Pharmacia Biotech Inc., 
Sweden) and kept at −20°C before the animal studies. 
2.3 In vitro expression of DNA vaccines 
Transfection of pCAG-HAk and pCAG-optiHAk into 293T and CEF cells was conducted 
with LipofectamineTM 2000 (Invitrogen, USA) following the manufacturer’s instructions. 
Forty eight hours after transfection, the cells were fixed with 75% ethanol for 30 min at 
room temperature. An immunofluorescence assay was performed using chicken anti-H6 
serum and FITC-conjugated rabbit anti-chicken IgG (Sigma-Aldrich, China). The 
monolayers were observed for specific green fluorescence under a Leica DMIRES2 
microscope (Leica, Germany). 
2.4 Animals, immunizations and antibody responses  
Vaccine trial experiments in SPF chickens were conducted in HEPA-filtered isolators. 
The plasmids were diluted in PBS to the desired concentration and administered, as 
indicated in Table 2 and 3, in a 200 µl volume to the leg muscle by either IM injection or 
EP. Three groups of 8 chickens each received either 10, 100 or 300 µg pCAG-HAk by 
IM injection (Groups 1-3); one group of 8 chickens received 100 µg pCAGGS by IM 
injection (Group 4) and one group of 8 chickens received 100 µg pCAG-HAk by EP 
(Group 5). Three weeks later, these five groups of birds were given booster vaccinations 
using the same dose and delivery route. Another group of 15 chickens (Group 6) received 
only a single vaccination of 100 µg pCAG-HAk by IM injection. Two other groups of 8 
chickens each received either 10 or 100 µg pCAG-optiHAk by IM injection followed 
three weeks later by booster vaccinations using the same dose and delivery route (Groups 
7 and 8).  











Blood was collected weekly from the wing vein of each chicken for testing of serum 
antibody levels to H6 HA.  Antibody was measured using the haemagglutination 
inhibition (HI) test as described previously with A/coot/WA/2727/79 (H6N2) virus as 
antigen (Shan, 2010). 
2.5 Data analysis 
Statistical analysis of HI antibody titers was conducted as geometric mean titers (GMT). 
Statistical analyses of experimental data were conducted by using one way analysis of 
variance (ANOVA) with SPSS statistical software version 15 as well as Chi-square 
(Fisher's exact test was used when the sample number was less than 5) using Statistix. 
Statistical significance was defined at the level of p<0.05. 
3. Results 
3.1 Effect of codon optimization on HA composition 
The chemically synthesized chicken codon-biased HA gene from A/ coot/WA/2727/79 
(H6N2) had the same HA amino acid sequences as the original virus, but the nucleotide 
homology between the wild-type HA gene and the codon-optimized HA gene was 74.8% 
(The nucleotide sequence comparison using ClustalW tool between them is not shown, 
but is available on request). A summary of the codon preference changes before and after 
codon optimization using EditSeq of DNASTAR is presented in Table 1. Codon 
optimization resulted in an increase in the G+C content from 41.3% in HA wild-type to 
59.5% after optimization. 
3.2 In vitro expression of the pCAG-HAk and pCAG-optiHAk constructs 











After cloning of the HA or codon optimized HA gene into the pCAGGS vector, the 
positive clones were screened by PCR and the resultant pCAG-HAk or pCAG-optiHAk 
construct was confirmed by restriction enzyme analysis and sequencing. Expression of 
influenza H6 HA by the plasmids was confirmed by immunostaining the transfected 
293T (shown in Fig. 1) and CEF cells. The pCAG-HAk or pCAG-optiHAk constructs 
showed similar intensity of fluorescence in either 293T or CEF cells.  
Table 1 Comparison of codon preference before and after codon optimization.  
Codon Codon Amino  
acid Original Codon optimization 
Amino 
 acid Original Codon optimization 
Ala GCA GCC Met AUG AUG 
Arg AGA AGA Leu UUG CUG 
Asn AAU AAC Lys AAA AAG 
Asp GAU GAU Phe UUC/UUU UUC 
Cys UGU UGC Pro CCA CCC 
Gln CAA CAG Ser UCA AGC 
Glu GAA GAG Thr ACA ACC 
Gly GGA GGC Trp UGG UGG 
His CAU CAC Tyr UAU UAC 
Ile AUA AUC Val GUG GUG 
3.3 Antibody response induced by two vaccinations of pCAG-HAk construct  
As shown in Table 2 (Groups 1 to 3), the earliest time of seroconversion appeared two 
weeks after vaccination. The H6 HI test seroconversion rates three weeks after initial 
vaccination were 37.5%, 12.5% and 0 in the 10, 100 and 300 µg pCAG-HAk vaccinated 
groups respectively. After the booster vaccination the seroconversion rate increased to 
87.5%, 75% and 75% respectively, indicating that a second vaccination increased the 
seroconversion rate in all three groups. 
The profile of HI antibodies induced by different doses of pCAG-HAk (Groups 1 to 3) 
during the 8-week study period was similar (Table 3). After one dose, the vaccinated 
birds in the 10 µg and 100 µg pCAG-HAk groups demonstrated HI antibody, but those in 











the 300 µg group did not. However, the H6 HI titer rose significantly in the three 
different dose groups following booster vaccination and reached a plateau 2-3 weeks 
post-booster. No H6 HI antibody was detected in the pCAGGS vaccinated group. The 
GMT of HI antibody was significantly different (Mann-Whitney Test, p<0.05) between 
the combined pCAG-HAk groups and the pCAGGS group at weeks 4, 5, 6, 7 and 8 
following initial vaccination, but there was no significant difference at week 3 after 
vaccination. There was no significant difference in GMT between the three doses of 
pCAG-HAk vaccine (ANOVA, P = 0.963). 
3.4 Antibody response induced by a single vaccination of the pCAG-HAk construct  
 
Of 15 birds vaccinated with a single dose of 100 µg pCAG-HAk construct, 40% (6/15) 
seroconverted at week 2 post-vaccination and 66.7% (10/15)  at week 5 post-vaccination 
(Group 6 in Table 2). The peak HI GMT occurred at week 5 post-vaccination and the HI 
titer slowly declined during the 3-month observation period. There were no significant 
differences (ANOVA, P>0.05) in the GMT of H6 HI antibody at weeks 2 and 3 post-
vaccination between  Group 6 and the pCAGGS vector group (Group 4). Neither was 
there a significant difference in the HI antibody (ANOVA, P=0.43) or in the sero-
conversion rate (Fisher's exact test, P=0.37) at week 3 following initial vaccination 
between Group 6 and Group 2 (Table 2 and Table 3). 
354 Antibody response induced by two vaccinations of pCAG-HAk construct via EP 
Birds administered pCAG-HAk construct via EP showed 87.5% seroconversion after the 
first vaccination and 100% seroconversion after the second vaccination (Group 5 in Table 
2 and Fig. 2).  The highest HI antibody GMT (27.1) occurred at week 5 post-vaccination, 
and then the antibody levels gradually declined. The highest HI titer for an individual 











bird was 211. There were significant differences (ANOVA/Mann-Whitney Test, P<0.05) 
in the HI antibody titers from week 2 to 8 between the IM and EP groups receiving 100 
µg pCAG-HAk. 











        Table 2 Seroconversion rate by H6 HI test in chickens immunized with pCAG-HAk, pCAG-optiHAk or pCAGGS. 
Seroconversion rate (weeks post vaccination) Group Vaccine Dose 
(µg) 
Route
1 2 3a 4 5 6 7 8 9 10 11 12 
1 pCAG-HAk 10 IM 0/8b A 1/8 A 3/8 A 4/8 A 6/8 A 6/8 A 7/8 A 7/8 B     
2 pCAG-HAk 100 IM 0/8 A 1/8 A 1/8 A 2/8 A 6/8 A 5/8 A 5/8 A 6/8 AB     
3 pCAG-HAk 300 IM 0/8 0/8  0/8 5/8 6/8 6/8 6/8 5/8     
4 pCAGGS 100 IM 0/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8     
5 pCAG-HAk 100 EP 1/8 5/8 7/8 8/8 8/8 8/8 8/8 8/8     
6 pCAG-HAk 100 IM 0/15 6/15 5/15 7/15 10/15 8/15 8/15 8/15 8/15 8/15 8/15 8/15
7 pCAG-optiHAk 10 IM 0/8A 0/8A 1/8 A 1/8 A 2/8 A 3/8 A 3/8 A 2/8 A 2/8 A    
8 pCAG-optiHAk 100 IM 0/8 A 2/8 A 3/8 A 3/8 A 4/8 A 4/8 A 7/8 A 7/8 B 7/8 B    
                  a Time of booster vaccination, except that group 6 was only vaccinated once. 
    bN/N represents HI antibody positive chickens/all vaccinated chickens. Within the column the different uppercase superscript letter indicates  
statistical differences (P < 0.05) using Fisher's exact test, group 3 to 6 excluded in statistical analysis. 
 
Table 3 HI titers in chickens immunized with pCAG-HAk, pCAG-optiHAk or pCAGGS over an 8- or 12- week period after vaccination. 
HI titer (weeks post vaccination) Vaccine Dose 
(µg) 
Route 
1 2 3 4 5 6 7 8 9 10 11 12 
pCAG-HAk 10 IM 0 a 0.4±1.1 0.9±1.4 1.6±2.1 2.4±2.1 2.8±2.1 3.1±2.0 3.2±2.1     
pCAG-HAk 100 IM 0 0.4±1.1 0.4±1.1 1.0±2.1 2.6±2.6 2.9±2.9 2.9±2.7 2.9±2.3     
pCAG-HAk 300 IM 0 0 0 1.5±1.7 2.6±2.2 2.6±2.0 2.3±1.7 1.9±1.8     
pCAGGS 100 IM 0 0 0 0 0 0 0 0     
pCAG-HAk 100 EP 0.1±0.4 3.3±3.4 3.8±2.8 6.7±3.0 7.1±3.0 6.6±2.3 5.8±2.4 5.6±2.1     
pCAG-HAk b 100 IM 0 1.0±1.4 0.9±1.4 2.0±2.5 2.4±2.3 2.1±2.2 1.8±1.9 1.7±1.8 1.5±1.6 1.3±1.3 1.1±1.2 1.1±1.2
pCAG-optiHAk 10 IM 0 0 0.1±0.2 0.4±1.1 1.3±2.5 1.4±2.5 1.1±2.0 1.2±2.2 1.2±2.2    
pCAG-optiHAk 100 IM 0 1.1±1.5 0.8±1.3 1.4±1.9 2.5±2.7 2.6±2.8 3.2±2.3 2.9±2.2 3.0±2.1    
a  H6 HI antibody GMT(log2± SD).   
b This group was only vaccinated once. The others were given a booster 3 weeks after initial immunization. 











3.6 Antibody response induced by two vaccinations of pCAG-optiHAk construct  
The kinetics of the antibody response induced by pCAG-optiHAk is shown in Table 2 
and 3. Following booster vaccination, the seroconversion rate and HI titers increased in 
both groups. The higher dose groups generated better immune responses than the lower 
dose groups in terms of the seroconversion rate, although there were no significant 
differences in the GMT of HI antibody between different doses of pCAG-optiHAk. This 
suggested that a 100 µg dose of pCAG-optiHAk was a more optimal dosage for induction 
of HI antibody responses.  
3.7 Comparison of HI titers between pCAG-HAk and pCAG-optiHAk groups 
The seroconversion rate and level of antibody response were compared between pCAG-
HAk and pCAG-optiHAk groups (Tables 2 and 3). There were no significant differences 
in the seroconversion rates from week 1 to week 7 after initial vaccination between either 
10 or 100 µg groups for pCAG-HAk and pCAG-optiHAk vaccines. Neither were there 
significant differences (ANOVA or Mann-Whitney, P>0.05) over an 8-week period in 
post vaccination antibody titers between pCAG-HAk and pCAG-optiHAk vaccines. Only 
at week 8 for the 10 µg dose groups was there a difference, with the pCAG-HAk group 
showing a higher seroconversion rate than the pCAG-optiHAk group.  
4. Discussion 
 
This study demonstrated that a pCAGGS vector encoding HA or codon optimized HA of 
a H6N2 virus, together with insertion of a Kozak sequence, was able to elicit measurable 
H6 HI antibody responses in SPF chickens. Either one or two vaccinations of naked 
plasmid DNA induced seroconversion in a substantial proportion of vaccinated chickens. 
Although the seroconversion rate following two vaccinations was similar in the three 











different dose groups, both 10 µg and 100 µg groups appeared to generate higher H6 HI 
geometric antibody titers than the 300 µg group although this was not significantly 
different. This observation that lower dose DNA vaccination was equivalent to or better 
than higher dose DNA vaccination for generating antibody responses was comparable to 
a previous evaluation by Shan (2010)  using four different HA-DNA vaccine constructs 
in chickens. In addition, vaccination with the 10 µg pCAG-HAk DNA plasmid dose via 
the IM route appeared to induce similar H6 HI antibody titers to the 100 µg DNA 
plasmid dose. In contrast, the 100 µg dose pCAG-optiHAk group seemed to elicit a better 
response than the 10 µg dose group. This underlined the critical need for optimization of 
DNA vaccine doses. 
In the group receiving a single dose of the 100 µg pCAG-HAk DNA vaccine, the 
antibody response at week 3 post-vaccination appeared stronger in terms of the sero-
conversion rate than that in the group with two injections of the same dose 3 weeks apart. 
However, the differences between the groups at week 3 post-vaccination were not 
significantly different and probably resulted from biological variation in individuals 
within the experimental groups. In addition, there was considerable individual variation 
in H6 HI antibody response among chickens inoculated intramuscularly with pCAG-HAk 
vaccine, or pCAG-optiHAk vaccine, or even those vaccinated using EP. This variation 
has also been reported in other DNA vaccine studies in chickens (Suarez and Schultz-
Cherry 2000) and mice (Ulmer et al., 1994). The reason for the wide variation in 
individual HI antibody titers in vaccinated birds is not clear, but may be attributable to 
the poor efficiency of the delivery method (Wang et al., 2008). This inter-individual 











variation is another drawback of DNA vaccines and highlights the need to fully elucidate 
the mechanism of the DNA-induced immune response. 
The temporal antibody response studies following pCAG-HAk vaccination with EP 
showed that the earliest detectable antibody was at one week post-vaccination, compared 
with two weeks via IM administration. However, in some IM vaccinated chickens the 
immune response was not detectable until 5 weeks post-vaccination. This long lag phase 
is probably related to poor DNA uptake into muscle fibers via IM delivery, the 
mechanism of which is poorly understood. It has been hypothesized that although IM 
injection of naked DNA vaccines only causes the transfection of a limited number of 
muscle fibers,, the low rate of muscle fiber turnover can result in the expression of the 
plasmid DNA for an extended period of time (Pertmer et al., 1996).  In addition, 
myocytes (long-lived cells that cannot re-enter mitosis) are terminally differentiated, thus 
they do not dilute out the internalized plasmids, resulting in long-term stability and 
transcriptional activity of plasmid DNA (Fattori et al., 2002). 
It has been established previously, based on disease signs and tracheal/cloacal virus 
isolation, that chickens given inactivated vaccines reaching a post-vaccination geometric 
mean HI titer of greater than 6.5 log2 had good protection against virus challenge (Wood 
et al., 1985). However, in vaccine challenge studies using field vaccinated birds with a 
H5 HI titer of 5.0 log 2 or higher, there was complete protection against a high challenge 
dose of Asian H5N1 HPAI (Ellis et al., 2004). A close relationship between HI titers 
generated by plasmid DNA (greater than 1:40) and protection was observed previously in 
mice, ferrets and non-human primates immunized with a plasmid encoding consensus HA 
gene of H5 avian influenza virus (Laddy et al., 2008). In the present studies a pilot trial 











was conducted (data not shown) in which 8-week-old unvaccinated SPF chickens were 
subjected to a challenge with a dose of 0.2 mL (106.17 EID50/0.1 mL) of 
A/duck/Anhui/269/2002 (H6N2) by intranasal instillation. There were no measurable 
clinical effects so it was decided not to include virus challenge studies of the H6 DNA 
vaccinated chickens and we can make no claims about the protective efficacy of these 
constructs. Nevertheless, one can expect that if protection against avian influenza 
infection is equated with a HI titer of 5.0 log 2 or higher, seven out of eight chickens in 
the 100 µg EP group and two (pCAG-HAk) or three (pCAG-optiHAk) out of eight birds 
in the 100 µg IM group had achieved this level of protection. 
EP has been well documented to increase the magnitude of the humoral and cellular 
responses induced by DNA vaccines in a range of animal models such as mice 
(Muthumani et al., 2008; Widera et al., 2000), rats (Zucchelli et al., 2000),  rabbits (Wang 
et al., 2008; Widera et al., 2000; Zucchelli et al., 2000), guinea pigs (Widera et al., 2000), 
goats and cattle (Tollefsen et al., 2003), sheep (Babiuk et al., 2007) and non-human 
primates (Luckay et al., 2007). In this study, all chickens vaccinated with the pCAG-HAk 
DNA vaccine via EP generated high titers of H6 antibody, comparable to titers previously 
achieved with an inactivated whole virus H6N2 vaccine in other experiemnts (Shan, 
2010). The mean H6 HI titer was ≥ 8-fold higher in the EP vaccinated group than in the 
IM vaccinated group from 2 to 8 weeks post-vaccination. This indicated that vaccination 
with EP was significantly more effective than routine IM inoculation with the pCAG-
HAk vaccine in chickens.  
In the current study, the virus HA gene sequence was also replaced by the chicken biased 
codon sequence, resulting in 25.2% alteration at the nucleotide level and 18.2% GC ratio 











increase in the codon-optimized HA DNA sequence, compared to the wild type virus 
sequence. The high GC content in the gene may be favorable for its mRNA stability, 
processing and nucleo-cytoplasmic transport (Haas et al., 1996; Jiang et al., 2007). This 
high GC rate could increase the number of CpG motifs in an optimized gene, which may 
act as an inherent adjuvant. Based on codon alteration, improvements in the 
immunogenicity of the optimized HA-encoding plasmid were expected, however, the 
codon optimized HA DNA vaccine did not achieve better immunogenicity in terms of 
seroconversion rate and HI titer than the wild type HA-expressing DNA vaccine. This has 
similarities with other studies in which  re-engineering the coding sequence with the most 
prevalent HIV-1 codons impaired considerably rat thymocyte protein (Thy-1) expression, 
but enhanced green fluorescent protein expression (Haas et al., 1996). 
Many factors regulate and influence gene expression levels. It has been assumed widely 
that translational initiation is responsible for translational efficiencies of mammalian gene 
products (Haas et al., 1996). The toeprinting assay used with mRNAs showed that the 
nucleotide G in position +4 augmented recognition of AUG and favored translation 
(Kozak 1987). Using the same codon optimization strategy as the current study for an 
optimized HA gene from A/goose/Guangdong/1/96 (H5N1)  the first amino acid 
following ATG was Glu (GAG)  and this construct achieved the expected increased 
immune response (Jiang et al., 2007).  In contrast,  in the current study with the optimized 
H6-HA gene, the first amino acid after ATG was Ile (ATC) and the nucleotide at the +4 
position was A rather than G.  This may have accounted for some suboptimal expression 
in chickens. Additionally, some factors such as mRNA secondary structure, internal 
TATA boxes, cryptic splicing sites, premature Polka sites, internal chi sites, ribosomal 











binding sites, negative CpG islands, RNA instability motif (ARE) and inhibition sites 
may all impact on ribosomal binding and stability of mRNA (Wang et al., 2006). Thus, 
expression of a codon biased gene may be further enhanced by RNA optimization. The 
codon optimization approach in this study needs to be further explored.  
The promoter driving gene expression was one of the factors affecting the efficacy of 
DNA vaccines (Suarez and Schultz-Cherry 2000). Previous experiments showed that four 
expression vectors (VR1012, pCI, pCI-neo and pVAX1) expressing the same HA gene 
under the control of the cytomegalovirus (CMV) promoter induced no or minimal 
antibody response in Hy-line chickens (Shan, 2010), even when co-administered with 
lipofectin as adjuvant. In the current study, insertion of the Kozak sequence and use of 
the pCAGGS vector, which contains an intron between the promoter and the HA ORF, 
under the control of the chicken β-actin promoter contributed to a higher level of H6 HA 
expression than the four DNA vaccines in previous studies, resulting in a detectable 
antibody response. Analyzing the parameters which impact on DNA-induced antibody 
responses is important to successfully develop DNA vaccines. Further investigation of 
these factors with this DNA construct is currently being undertaken.   
To conclude, this study showed that DNA vaccines can induce antibody response in 
chickens to H6N2 avian influenza virus by selection of an appropriate vector and 
insertion of a Kozak sequence. Electroporation was an effective method to enhance the 
potency of DNA vaccines. However, codon optimization did not seem to demonstrate the 
expected enhancing effect.      
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Fig. 1. Photomicropgraphs of immunofluorescent staining for H6 avian influenza 
antigens in 293T cells transfected with (a) pCAG-optiHAk, (b) pCAG-HAk, (c) 
pCAGGS only. (Leica DMIRES2, x100). 
 
 
Fig. 2. Temporal changes in H6 HI titer over an 8-week period post-vaccination in 
chickens immunized with 100 µg pCAG-HAk via EP. The curve represents the mean 
antibody titer of the group. Each icon number refers to one bird. 
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